A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Latest Information Update: 06 Sep 2024
At a glance
- Drugs AZD 1222 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 23 Jun 2023 Results from four (NCT04470427, NCT04516746, NCT04505722, and NCT04611802) COVID-19 prevention network efficacy trials published in the Vaccine
- 10 Mar 2023 Status changed from active, no longer recruiting to completed.
- 15 Sep 2022 Results reporting durability of protection and immunogenicity published in the Journal of Clinical Investigation